Sumitomo Mitsui Trust Group Inc. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,023,264 shares of the medical research company's stock after acquiring an additional 38,307 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.56% of IQVIA worth $242,483,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. 1832 Asset Management L.P. increased its position in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $70,610,000. Impax Asset Management Group plc raised its position in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after purchasing an additional 264,555 shares during the period. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock worth $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in IQVIA by 285.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock valued at $56,783,000 after purchasing an additional 198,808 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.
Insider Buying and Selling at IQVIA
In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have commented on IQV shares. Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Morgan Stanley dropped their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Robert W. Baird reduced their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, Argus upgraded shares of IQVIA to a "strong-buy" rating in a research note on Wednesday, July 31st. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $259.13.
Get Our Latest Report on IQVIA
IQVIA Price Performance
NYSE IQV traded down $2.08 on Wednesday, reaching $211.49. 3,190,976 shares of the company's stock traded hands, compared to its average volume of 1,118,086. The stock has a market cap of $38.39 billion, a PE ratio of 27.75, a P/E/G ratio of 2.20 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 12 month low of $197.37 and a 12 month high of $261.73. The stock has a 50-day simple moving average of $229.61 and a 200 day simple moving average of $228.89.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
